Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Facilitating Web-based Patient Decision Support: Decision About Medication to Lower Breast Cancer Risk

NCT00906321 · View on ClinicalTrials.gov ↗

Study Summary

Background: * Chemoprevention is the use of preventive medications to reduce the risk of breast cancer for women who are at a high risk of developing the disease. Although the treatment has shown effectiveness in preventing cancer development, chemoprevention is notably underutilized even by women who are at a high risk of developing breast cancer. * Researchers are interested in determining if better decision support mechanisms, such as interactive Web sites, can help to overcome some of the barriers to chemoprevention. Objectives: \- To develop and test a prototype Web-based module that will provide decision support to women who are considering chemoprevention for breast cancer. Eligibility: * Women 35 years of age and older who are at high risk for breast cancer and whose doctor has recommended chemoprevention (either Tamoxifen or Raloxifene), and who have no other history of cancer (apart from non-melanoma skin cancer or precancerous cervical lesions). * Participants must have a working e-mail address and access to a computer with internet access and a telephone. Design: * Participants who are considering chemoprevention will be randomized to a Web-based decision support module or standard care online information resources. * Participation lasts two months and involves using the online resources provided and filling out questionnaires two times during the study (at the beginning and the end). The first time will be at the begin of the study. * No medical treatments are offered as a part of this study

Interventions

  • BEHAVIORAL Web-Based Decision Support

Study Locations (1)

Maryland

  • National Cancer Institute (NCI), 9000 Rockville Pike — Bethesda

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2009-05-18
Est. Completion 2010-05-26
Phase NA

Sponsor

National Cancer Institute (NCI)

2,390 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00906321

The ClinicalTrials.gov registry entry for NCT00906321 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 2,390 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Risk Reduction Behavior appearing as the primary indexed condition, and to 1 intervention — of which Web-Based Decision Support is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00906321 reports 1 study location spanning 1 distinct geographic area — top geographies include Maryland. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00906321 about?

NCT00906321 is a clinical study titled "Facilitating Web-based Patient Decision Support: Decision About Medication to Lower Breast Cancer Risk". Background: * Chemoprevention is the use of preventive medications to reduce the risk of breast cancer for women who are at a high risk of developing the disease. Although the treatment has shown effectiveness in preventing cancer development, chemoprevention is notably underutilized even by women ...

What is the current status of trial NCT00906321?

This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2009-05-18. Estimated completion is 2010-05-26.

What conditions does trial NCT00906321 study?

This clinical trial studies the following conditions: Risk Reduction Behavior, High Risk for Breast Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00906321?

The interventions under investigation include: Web-Based Decision Support (BEHAVIORAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00906321?

This trial is sponsored by National Cancer Institute (NCI), which has 2,390 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00906321 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial